Meeting
2022 ASCO Quality Care Symposium
Real-world treatment patterns among patients with non-muscle invasive bladder cancer (NMIBC) treated with intravesical Bacillus Calmette-Guerin (BCG).
Authors
Neela Kumar
Janssen Scientific Affairs, LLC, Horsham, PA
Neela Kumar, Hiremagalur parthasarathy Balaji, Bruno Emond, Ameur M Manceur, Isabelle Ghelerter, Dominic Pilon, Patrick Lefebvre, Nida Shafaat Imran, Lorie Ellis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 404)
DOI
10.1200/JCO.2022.40.28_suppl.404
Abstract #
404
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Franklin D Gaylis
Poster
2023 ASCO Genitourinary Cancers Symposium
Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
First Author: Zhiyong Li
Poster
2023 ASCO Genitourinary Cancers Symposium
Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010-2019.
First Author: Allison A. Petrilla
Poster
2024 ASCO Genitourinary Cancers Symposium
Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
First Author: Zongren Wang